Over at Fast-Track Millionaire, our mandate requires us to stay abreast of the most recent scientific achievements.  And how could it be any other way? Most game-changing companies change the game by either finding real-life applications for modern scientific or technological discoveries or using those discoveries to modernize or disrupt entire businesses or industries.  We’ve had good success with these types of investments so far — but they don’t come close to the kind of potential I’m seeing in one field in particular…  I’m talking about the up-and-coming field of personalized medicine. —Recommended Link— Congratulations On 10 Years Of Profits… Read More

Over at Fast-Track Millionaire, our mandate requires us to stay abreast of the most recent scientific achievements.  And how could it be any other way? Most game-changing companies change the game by either finding real-life applications for modern scientific or technological discoveries or using those discoveries to modernize or disrupt entire businesses or industries.  We’ve had good success with these types of investments so far — but they don’t come close to the kind of potential I’m seeing in one field in particular…  I’m talking about the up-and-coming field of personalized medicine. —Recommended Link— Congratulations On 10 Years Of Profits We’ve unleashed it again — our annual Game-Changing Predictions report, filled cover-to-cover with a dozen potentially life-changing picks for 2019. And to mark this 10th anniversary edition, we’re doing something a little different… In addition to the full write up on each prediction (complete with the tickers), the first 250 readers to claim their copy will get instant access to 2 additional “bonus picks” that are positioned to bring home double… even triple-digit gains in 2019. If the thought of an extra $1,543… $2,184… even $4,200 each month in cash sounds good to you, click here now to see if… Read More

It’s only been a little over three months since marijuana became legal in Canada, but the country’s government statistics agency has already added a relevant report to its monthly data set. Statistics Canada, the national statistical office, now reports revenues generated by cannabis as part of its standard monthly retail sales report. And thanks to that addition, we learned on Jan. 23 that Canadians bought $41 million (U.S. dollars) of marijuana from retail stores in November, the first full month since the legalization became a fact of life. If anything, this number is an understatement of the true market size… Read More

It’s only been a little over three months since marijuana became legal in Canada, but the country’s government statistics agency has already added a relevant report to its monthly data set. Statistics Canada, the national statistical office, now reports revenues generated by cannabis as part of its standard monthly retail sales report. And thanks to that addition, we learned on Jan. 23 that Canadians bought $41 million (U.S. dollars) of marijuana from retail stores in November, the first full month since the legalization became a fact of life. If anything, this number is an understatement of the true market size for legal pot in Canada. Retail stores are still opening; Ontario, the country’s largest state, still hasn’t opened any retail stores (in this state, sales are still limited to online orders). Further, the demand was so strong that a number of stores ran out of product. Canopy Growth: Best In The Business In the three months since I first added Canada’s Canopy Growth Corp. (NYSE: CGC) to the our Fast-Track Millionaire portfolio, the stock has handily outperformed its closest peer, Tilray (Nasdaq: TLRY). While TILR has lost nearly 30% of its value over these three months, CGC has appreciated by more… Read More

It’s been hard not to notice how slow this year has been when it comes to bringing new companies to the market via initial public offerings (IPOs).  Last quarter’s market selloff plus government shutdown-related staffing issues at regulatory agencies such as the Securities and Exchange Commission are largely to blame. As of last Friday, Jan. 18, only three companies had gone public so far this year, with another expected to make its debut on Jan. 25. In January 2018, by contrast, 20 companies had IPO-ed. This pace puts the IPO market of 2019 well behind the rate needed to match… Read More

It’s been hard not to notice how slow this year has been when it comes to bringing new companies to the market via initial public offerings (IPOs).  Last quarter’s market selloff plus government shutdown-related staffing issues at regulatory agencies such as the Securities and Exchange Commission are largely to blame. As of last Friday, Jan. 18, only three companies had gone public so far this year, with another expected to make its debut on Jan. 25. In January 2018, by contrast, 20 companies had IPO-ed. This pace puts the IPO market of 2019 well behind the rate needed to match or exceed the breakneck activity of 2018 when 190 companies went public.  But this does not mean we cannot learn or benefit from the IPO market — these 190 recently-minted public companies offer a lot of new ideas and fresh profit opportunities.  Because of the sheer number of these fledgling companies, I had to first narrow down my area of interest. At this time, I’m focusing on the consumer discretionary sector. With numerous innovations hitting the consumer market, I thought it would be interesting to see how well these companies are being received by the investing public.  Hence, today’s… Read More

When Thomas Edison died, or Einstein, or Dr. Feynman, for that matter… we knew what we had lost. The scientific community grieved. But when a scientist whose discovery might prove to be in any one or even all of their leagues died on Feb. 18 of last year, it felt as though the news went almost unnoticed. Gunter Blobel was a molecular biologist. In 1999, he was awarded the Nobel Prize in medicine. He had determined that proteins in any living cell have a sort of ZIP code system that guides them to where they need to go to take… Read More

When Thomas Edison died, or Einstein, or Dr. Feynman, for that matter… we knew what we had lost. The scientific community grieved. But when a scientist whose discovery might prove to be in any one or even all of their leagues died on Feb. 18 of last year, it felt as though the news went almost unnoticed. Gunter Blobel was a molecular biologist. In 1999, he was awarded the Nobel Prize in medicine. He had determined that proteins in any living cell have a sort of ZIP code system that guides them to where they need to go to take care of tissue, organs, and biochemistry. Blobel’s mentor at Rockefeller University, Dr. George Palade, was a wizard with electron microscopes — his work earned him the Nobel in 1974. Blobel figured out that there are about a quadrillion cells in the human body, each containing about a billion protein molecules that are spun out of little cavities known as endoplasmic reticula. These proteins are all guarded by special membranes. He and a colleague hypothesized that each of these proteins also contains proteins that act as airport luggage tags, as his obituary in the Times put it. It turns out this… Read More